Protalix Biotherapeutics Inc (PLX) — Capital Reinvestment Ratio
Protalix Biotherapeutics Inc (PLX) has a Capital Reinvestment Ratio of 0.61x as of December 2025, meaning it reinvests 1% of its operating cash flow ($2.03 Million) in capital expenditures ($1.24 Million). Check PLX intangible-adjusted equity ratio to evaluate the tangible quality of the company's equity base.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Protalix Biotherapeutics Inc Capital Reinvestment Ratio (2009–2024)
This chart tracks Protalix Biotherapeutics Inc's Capital Reinvestment Ratio across 3 annual periods. For the full cash flow conversion analysis, see Protalix Biotherapeutics Inc (PLX) cash conversion ratio.
Annual Capital Reinvestment Ratio for Protalix Biotherapeutics Inc (2009–2024)
Year-by-year Capital Reinvestment Ratio for Protalix Biotherapeutics Inc from 2009 to 2024. See Protalix Biotherapeutics Inc free cash flow generation to measure how efficiently the company converts operating cash flow to free cash.
| Year | Reinvestment Ratio | Operating CF (USD) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2024 | 0.15x | $8.67 Million | $1.28 Million | ▼ -95.5% |
| 2012 | 3.26x | $635.00K | $2.07 Million | ▲ +2236.8% |
| 2009 | 0.14x | $44.45 Million | $6.20 Million | — |